Last reviewed · How we verify
NCT02880163: REVIVE
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
NA trial testing ResQFoam in Hemorrhagic Shock in 40 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Arsenal Medical, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 August 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- ResQFoam
Conditions studied
- Hemorrhagic Shock — all drugs for Hemorrhagic Shock →
- Trauma — all drugs for Trauma →
- Exsanguinating Hemorrhage — all drugs for Exsanguinating Hemorrhage →
- Shock; Traumatic — all drugs for Shock; Traumatic →
Sponsor
Arsenal Medical, Inc.
Who can join
15 and older, any sex, with Hemorrhagic Shock or Trauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Traumatic hemorrhage and chain of survival.
Latif RK, Clifford SP, Baker JA, Lenhardt R, et al · · 2023 · cited 74× · PMID 37226264 · DOI 10.1186/s13049-023-01088-8 -
Hemostatic agents for prehospital hemorrhage control: a narrative review.
Peng HT. · · 2020 · cited 70× · PMID 32209132 · DOI 10.1186/s40779-020-00241-z -
Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage.
Klein MK, Kassam HA, Lee RH, Bergmeier W, et al · · 2020 · cited 30× · PMID 32469498 · DOI 10.1021/acsnano.9b09243 -
Optimizing transfusion strategies in damage control resuscitation: current insights.
Pohlman TH, Fecher AM, Arreola-Garcia C. · · 2018 · cited 5× · PMID 30154676 · DOI 10.2147/jbm.s165394
Verify or expand the search:
- PubMed search for NCT02880163
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemorrhagic Shock
Currently open trials in the same condition.
- NCT07105904 — Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery · active not recruiting
- NCT06070350 — Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02880163 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arsenal Medical, Inc.
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02880163.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing